MARATTO

article · Medical Mycology Case Reports

Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda

20241 citationOpen accessMakerere University

Abstract

Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.

Research topics

  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.mmcr.2024.100666

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.